Payment overview · 2025
General Payments
$200.92
10 reported records · 7 companies
Healthcare provider profile · identity verified
Timothy J Wagner, MD
Allopathic & Osteopathic Physicians|Family Medicine · SHINER, TX · NPI 1851372619
Verified facts
What the public records show
CMS Open Payments records show Timothy J Wagner, MD received $200.92 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.66 | 30.2% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $43.47 | 21.6% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $37.59 | 18.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.00 | 9.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.66 | 8.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.37 | 8.7% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $5.17 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $200.92 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.66 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.66 | 3 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $43.47 | 2 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $37.59 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Pharmaceuticals, Inc | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Pharmaceuticals, Inc | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Pharmaceuticals, Inc | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $5.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 339 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 302 | 53 |
| Lisinopril | Lisinopril | 302 | 61 |
| Furosemide | Furosemide | 294 | 46 |
| Losartan Potassium | Losartan Potassium | 223 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 182 | 24 |
| Meloxicam | Meloxicam | 182 | 50 |
| Allopurinol | Allopurinol | 166 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 140 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 33 |
| Metformin Hcl | Metformin Hcl | 130 | 29 |
| Alendronate Sodium | Alendronate Sodium | 124 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 123 | 14 |
| Donepezil Hcl | Donepezil Hcl | 114 | 17 |
| Eliquis | Apixaban | 114 | 17 |
| Mirtazapine | Mirtazapine | 113 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 20 |
| Gabapentin | Gabapentin | 97 | 22 |
| Finasteride | Finasteride | 93 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 15 |
| Alprazolam | Alprazolam | 87 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 87 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 17 |
| Omeprazole | Omeprazole | 81 | 18 |
| Glipizide | Glipizide | 74 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 73 | 17 |
| Buspirone Hcl | Buspirone Hcl | 71 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | suppressed |
| Simvastatin | Simvastatin | 68 | 15 |
| Montelukast Sodium | Montelukast Sodium | 64 | 11 |
| Januvia | Sitagliptin Phosphate | 62 | suppressed |
| Azithromycin | Azithromycin | 60 | 47 |
| Carvedilol | Carvedilol | 59 | suppressed |
| Methylprednisolone | Methylprednisolone | 58 | 46 |
| Spironolactone | Spironolactone | 58 | 17 |
| Cefuroxime | Cefuroxime Axetil | 57 | 45 |
| Atenolol | Atenolol | 56 | suppressed |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Entacapone | Entacapone | 51 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 30 |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 46 | suppressed |
| Potassium Chloride | Potassium Chloride | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | 15 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 42 | 11 |
| Terazosin Hcl | Terazosin Hcl | 41 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 40 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Lorazepam | Lorazepam | 39 | suppressed |
| Prednisone | Prednisone | 39 | 27 |
| Colestipol Hcl | Colestipol Hcl | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 28 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 18 |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $200.92 · 10 records | Lilly USA, LLC | Cologuard Collection Kit, DARZALEX, KEYTRUDA, KEYTRUDA QLEX, MOUNJARO, NEXPLANON, TALVEY, TECVAYLI, Vonjo, WELIREG, YUPELRI, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error